Hydroxychloroquine and systemic lupus: a reappraisal;Hydroxychloroquine dans le traitement du lupus : le renouveau

Revue de Medecine Interne

Volumn 29, Issue 9, 2008, Pages 735-737

  Costedoat Chalumeau, N ^a   Leroux, G ^a   Amoura, Z ^a   Piette, J C ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

Drug dosage; Hydroxychloroquine; Systemic lupus erythematosus; Therapeutic drug monitoring

Indexed keywords

CORTICOSTEROID; HYDROXYCHLOROQUINE;

BONE DENSITY; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; DRUG CONTRAINDICATION; DRUG EFFICACY; HEALTH CARE UTILIZATION; HUMAN; INCIDENCE; MEDICAL INSTRUMENTATION; PRESCRIPTION; RARE DISEASE; RETINOPATHY; RISK ASSESSMENT; SCREENING TEST; SHORT SURVEY; SIDE EFFECT; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 50049112116     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2007.05.031     Document Type: Short Survey

References (40)

1. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N. Engl. J. Med. 324 (1991) 150-154
2. Tsakonas E., Joseph L., Esdaile J.M., Choquette D., Senecal J.L., Cividino A., et al., The Canadian Hydroxychloroquine Study Group. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. Lupus 7 (1998) 80-85
3. Petri M., Alarcon G.S., Kimberly R.P., and Reveille J.D. Predictors of Renal Insufficiency in Systemic Lupus Erythematosus. Arthritis Rheum. 52 supplement (2005) S385 (abstract)
4. Kasitanon N., Fine D.M., Haas M., Magder L.S., and Petri M. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 15 (2006) 366-370
5. Fessler B.J., Alarcon G.S., McGwin Jr. G., Roseman J., Bastian H.M., Friedman A.W., et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 52 (2005) 1473-1480
6. Edwards M.H., Pierangeli S., Liu X., Barker J.H., Anderson G., and Harris E.N. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 96 (1997) 4380-4384
7. Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand. J. Rheumatol. 25 (1996) 191-193
8. Mok M.Y., Chan E.Y., Fong D.Y., Leung K.F., Wong W.S., and Lau C.S. Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus. J. Rheumatol. 32 (2005) 622-628
9. Lakshminarayanan S., Walsh S., Mohanraj M., and Rothfield N. Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J. Rheumatol. 28 (2001) 102-108
10. Mok C.C., Mak A., and Ma K.M. Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus 14 (2005) 106-112
11. Roman M.J., Shanker B.A., Davis A., Lockshin M.D., Sammaritano L., Simantov R., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349 (2003) 2399-2406
12. Rahman P., Gladman D.D., Urowitz M.B., Yuen K., Hallett D., and Bruce I.N. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J. Rheumatol. 26 (1999) 325-330
13. Petri M., Lakatta C., Magder L., and Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am. J. Med. 96 (1994) 254-259
14. Hodis H.N., Quismorio Jr. F.P., Wickham E., and Blankenhorn D.H. The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J. Rheumatol. 20 (1993) 661-665
15. Wallace D.J., Metzger A.L., Stecher V.J., Turnbull B.A., and Kern P.A. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am. J. Med. 89 (1990) 322-326
16. Munro R., Morrison E., McDonald A.G., Hunter J.A., Madhok R., and Capell H.A. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann. Rheum. Dis. 56 (1997) 374-377
17. Ruiz-Irastorza G., Egurbide M.V., Pijoan J.I., Garmendia M., Villar I., Martinez-Berriotxoa A., et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 15 (2006) 577-583
18. Alarcon G.S., McGwin Jr. G., Bertoli A.M., Fessler B.J., Calvo-Alen J., Bastian H.M., et al. Effect of hydroxychloroquine in the survival of patients with systemic lupus erythematosus. data from lumina, a multiethnic US cohort (LUMINA L). Ann. Rheum. Dis. (2007) (sous presse)
19. e éd (2006), Éditions du Vidal, Issy-les-Moulineaux
20. Mates M., Zevin S., Breuer G.S., Navon P., and Nesher G. Desensitization to hydroxychloroquine - experience of 4 patients. J. Rheumatol. 33 (2006) 814-816
21. Ostensen M., Khamashta M., Lockshin M., Parke A., Brucato A., Carp H., et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res. Ther. 8 (2006) 209
22. Costedoat-Chalumeau N., Amoura Z., Duhaut P., Huong du L.T., Sebbough D., Wechsler B., et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum. 48 (2003) 3207-3211
23. Costedoat-Chalumeau N., Amoura Z., Huong du L.T., Lechat P., and Piette J.C. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Autoimmun. Rev. 4 (2005) 111-115
24. Winn Chatham W. Frequency and reasons for intolerance to antimalarials in patients with SLE: variability by drug preparation. Arthritis Rheum. 54 Supplement (2006) S441 (abstract)
25. Stein M., Bell M.J., and Ang L.C. Hydroxychloroquine neuromyotoxicity. J. Rheumatol. 27 (2000) 2927-2931
26. Costedoat-Chalumeau N., Hulot J.S., Amoura Z., Delcourt A., Maisonobe T., Dorent R., et al. Cardiomyopathy related to antimalarial therapy with Iillustrative case report. Cardiology 107 (2006) 73-80
27. Chernof D., and Taylor K.S. Hydroxychloroquine-induced agranulocytosis. Arch. Dermatol. 97 (1968) 163-164
28. Propp R.P., and Stillman J.S. Agranulocytosis and hydroxychloroquine. N. Engl. J. Med. 277 (1967) 492-493
29. Marmor M.F. The dilemma of hydroxychloroquine screening: new information from the multifocal ERG. Am. J. Ophthalmol. 140 (2005) 894-895
30. Marmor M.F. New American Academy of Ophthalmology recommendations on screening for hydroxychloroquine retinopathy. Arthritis Rheum. 48 (2003) 1764
31. Levy G.D., Munz S.J., Paschal J., Cohen H.B., Pince K.J., and Peterson T. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum. 40 (1997) 1482-1486
32. Marmor M.F., Carr R.E., Easterbrook M., Farjo A.A., and Mieler W.F. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 109 (2002) 1377-1382
33. Rigaudiere F., Ingster-Moati I., Hache J.C., Leid J., Verdet R., Haymann P., et al. Surveillance ophtalmologique de la prise des antipaludéens de synthèse au long cours : mise au point et conduite à tenir à partir de 2003. J. Fr. Ophtalmol. 27 (2004) 191-199
34. Costedoat-Chalumeau N., Amoura Z., Hulot J.S., Hammoud H.A., Aymard G., Cacoub P., et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 54 (2006) 3284-3290
35. Costedoat-Chalumeau N., Amoura Z., Hulot J.S., Aymard G., Leroux G., Marra D., et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann. Rheum. Dis. 66 (2007) 821-824
36. Burt R.K., Traynor A., Statkute L., Barr W.G., Rosa R., Schroeder J., et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 295 (2006) 527-535
37. Sanchez-Guerrero J., Uribe A.G., Jimenez-Santana L., Mestanza-Peralta M., Lara-Reyes P., Seuc A.H., et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N. Engl. J. Med. 353 (2005) 2539-2549
38. Petri M., Kim M.Y., Kalunian K.C., Grossman J., Hahn B.H., Sammaritano L.R., et al. Combined oral contraceptives in women with systemic lupus erythematosus. N. Engl. J. Med. 353 (2005) 2550-2558
39. Ginzler E.M., Dooley M.A., Aranow C., Kim M.Y., Buyon J., Merrill J.T., et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. 353 (2005) 2219-2228
40. Karim M.Y., Alba P., Cuadrado M.J., Abbs I.C., D'Cruz D.P., Khamashta M.A., et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford) 41 (2002) 876-882